Overview

Vitamin A and D Supplementation in Allogeneic HCT

Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.
Phase:
PHASE2
Details
Lead Sponsor:
St. Petersburg State Pavlov Medical University
Treatments:
Cholecalciferol
Vitamin A